Hologic Shares Surge 7.7% Amid Reports of New Acquisition Offer
ByAinvest
Thursday, Sep 18, 2025 10:57 am ET1min read
HOLX--
The investment firms have re-engaged with Hologic’s board about a potential takeover and are currently conducting due diligence, according to Bloomberg. This renewed interest comes after the Financial Times reported in May that Blackstone and TPG had approached Hologic with an offer exceeding $16 billion, which was rejected at the time [1].
Despite the positive news, Hologic remains down 16.8% over the past 12 months. However, the company's stock has shown resilience, with several analysts maintaining a positive outlook. Hologic received an average "Moderate Buy" rating and a price target of $78.00, according to data from MarketBeat [2].
The company reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year. Hologic's quarterly revenue was up 1.2% on a year-over-year basis, and the company has set its Q4 2025 guidance at 1.090-1.120 EPS. The FY 2025 guidance is at 4.230-4.260 EPS [2].
Institutional investors have also shown interest in Hologic. United Services Automobile Association bought a new stake in shares of Hologic during the first quarter, valued at approximately $347,000. Other hedge funds and institutional investors own 94.73% of the company's stock [3].
The renewed takeover interest and positive earnings reports suggest that Hologic may be on the path to recovery. However, any potential deal is still weeks away and there’s no certainty the talks will result in a transaction. Hologic and the investment firms have not publicly commented on the renewed takeover interest [1].
Hologic Inc. (NASDAQ:HOLX) shares jumped 7.69% to $68.20 on Wednesday amid reports of a renewed $16.7 billion takeover bid from Blackstone and TPG. The company has raised its revenue forecast for FY2025 to $4.08-$4.09 billion and expects Q4 revenues to hit $1.03-$1.04 billion.
Hologic Inc. (NASDAQ:HOLX) shares jumped 7.69% to $68.20 on Wednesday amid reports of a renewed $16.7 billion takeover bid from Blackstone and TPG. The medical device maker's stock has been an attractive acquisition target due to its recent stock performance challenges and the potential strategic value of its women's health products [1].The investment firms have re-engaged with Hologic’s board about a potential takeover and are currently conducting due diligence, according to Bloomberg. This renewed interest comes after the Financial Times reported in May that Blackstone and TPG had approached Hologic with an offer exceeding $16 billion, which was rejected at the time [1].
Despite the positive news, Hologic remains down 16.8% over the past 12 months. However, the company's stock has shown resilience, with several analysts maintaining a positive outlook. Hologic received an average "Moderate Buy" rating and a price target of $78.00, according to data from MarketBeat [2].
The company reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year. Hologic's quarterly revenue was up 1.2% on a year-over-year basis, and the company has set its Q4 2025 guidance at 1.090-1.120 EPS. The FY 2025 guidance is at 4.230-4.260 EPS [2].
Institutional investors have also shown interest in Hologic. United Services Automobile Association bought a new stake in shares of Hologic during the first quarter, valued at approximately $347,000. Other hedge funds and institutional investors own 94.73% of the company's stock [3].
The renewed takeover interest and positive earnings reports suggest that Hologic may be on the path to recovery. However, any potential deal is still weeks away and there’s no certainty the talks will result in a transaction. Hologic and the investment firms have not publicly commented on the renewed takeover interest [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet